The Global Hyaluronic Acid Viscosupplementation Market was valued at USD 5.21 Billion in 2024 and is projected to reach USD 8.72 Billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 8.9% during the forecast period (2024–2030). This robust growth is fueled by a rising global geriatric population, increasing prevalence of osteoarthritis, advancements in intra-articular injection technologies, and a growing patient preference for minimally invasive treatment options over surgical interventions.

As the demand for effective osteoarthritis management solutions surges, the focus intensifies on the key pharmaceutical and medical device companies that are pioneering novel formulations and delivery systems. In this analysis, we profile the Top 10 Companies in the Hyaluronic Acid Viscosupplementation Industry—a blend of established market leaders and innovative biotech firms shaping the future of joint health.

Download FREE Sample Report:
Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

---

🔟 1. Sanofi (acquired Synvisc portfolio from Genzyme)

Headquarters: Paris, France
Key Offering: Synvisc, Synvisc-One

Sanofi, through its acquisition of the Synvisc brand, is a dominant force in the viscosupplementation market. Synvisc-One is a popular single-injection hyaluronic acid product designed to provide up to six months of osteoarthritis knee pain relief, offering significant patient convenience.

Innovation and Market Initiatives:

• Market leader with high brand recognition for Synvisc-One
• Extensive clinical data supporting efficacy and safety
• Strong direct-to-consumer and physician education marketing

---

9️⃣ 2. Anika Therapeutics, Inc.

Headquarters: Bedford, Massachusetts, USA
Key Offering: Monovisc, Cingal, Orthovisc

Anika Therapeutics specializes in therapeutics based on hyaluronic acid. Its portfolio includes both single-injection (Monovisc) and combination products (Cingal, which combines HA with a steroid), addressing diverse patient needs and treatment preferences.

Innovation and Market Initiatives:

• Diverse product portfolio for different treatment protocols
• Proprietary HA technology platform (Hyalofast, Hyaloglide)
• Strategic focus on combination products for enhanced efficacy

---

8️⃣ 3. Ferring Pharmaceuticals (through acquisition of Zimme)

Headquarters: Saint-Prex, Switzerland
Key Offering: Euflexxa, Zilretta (via partnership)

Ferring Pharmaceuticals is a key player, particularly known for Euflexxa, a bioengineered, non-avian sourced HA product that is well-suited for patients with bird allergies. Their strategic acquisitions have strengthened their position in the musculoskeletal market.

Innovation and Market Initiatives:

• Bioengineered HA, reducing allergenic potential
• Focus on differentiated products for specific patient segments
• Global commercial footprint supporting market access

Download FREE Sample Report:
Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

---

7️⃣ 4. Seikagaku Corporation

Headquarters: Tokyo, Japan
Key Offering: Artz, ArtzDispo

Seikagaku Corporation is a leading Japanese pharmaceutical company with a long history in hyaluronic acid research. Its Artz brand is a well-established viscosupplement in the Asian market and other regions, known for its high purity and quality.

Innovation and Market Initiatives:

• Pioneer in HA research and manufacturing
• Strong presence in the Asia-Pacific region
• Continuous investment in R&D for next-generation formulations

---

6️⃣ 5. Fidia Farmaceutici S.p.A.

Headquarters: Abano Terme, Italy
Key Offering: HYMOVIS, GO-ON

Fidia Farmaceutici is a global specialist in hyaluronic acid-based products. HYMOVIS is an innovative viscosupplement noted for its viscoelastic properties and two-injection regimen, designed to restore joint homeostasis effectively.

Innovation and Market Initiatives:

• Focus on high molecular weight HA formulations
• Proprietary HYAFF® technology platform
• Expanding clinical evidence for product differentiation

---

5️⃣ 6. Zimmer Biomet Holdings, Inc.

Headquarters: Warsaw, Indiana, USA
Key Offering: GELSYN-3, GELSYN-3 Single Syringe

Zimmer Biomet, a leader in musculoskeletal healthcare, offers the GELSYN-3 viscosupplement. Leveraging its vast distribution network and strong relationships with orthopedic surgeons, the company holds a significant share in the market.

Innovation and Market Initiatives:

• Integration of viscosupplements within a broader orthopedic portfolio
• Direct access to a large network of orthopedic specialists
• Focus on procedural solutions and patient pathways

---

4️⃣ 7. LG Chem Ltd. (Life Sciences Division)

Headquarters: Seoul, South Korea
Key Offering: Hyruan, Hyruan Plus

LG Chem is a major South Korean chemical company whose Life Sciences division produces the Hyruan series of viscosupplements. The company benefits from robust in-house HA manufacturing capabilities and a strong position in Asian markets.

Innovation and Market Initiatives:

• Vertical integration in HA production
• Strategic expansion into international markets
• Investment in developing advanced drug delivery systems

---

3️⃣ 8. Bioventus Inc.

Headquarters: Durham, North Carolina, USA
Key Offering: DUROLANE, GELSYN-3 (following acquisition)

Bioventus is dedicated to developing and commercializing clinically proven therapeutic solutions. Its DUROLANE product is a single-injection HA viscosupplement stabilized to provide longer-lasting cushioning in the joint.

Innovation and Market Initiatives:

• Focus on “active healing” solutions
• Portfolio expansion through strategic acquisitions
• Building a comprehensive nonsurgical osteoarthritis portfolio

Download FREE Sample Report:
Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

---

2️⃣ 9. Viatris Inc. (includes Meda Pharma’s Sinovial portfolio)

Headquarters: Canonsburg, Pennsylvania, USA
Key Offering: Sinovial, Visco-3

Viatris, formed from the merger of Mylan and Upjohn, holds a significant viscosupplement portfolio inherited from Meda Pharma. The company leverages its extensive global commercial infrastructure to market these products widely.

Innovation and Market Initiatives:

• Broad global reach and market access capabilities
• Portfolio of both single and three-injection regimens
• Focus on providing affordable access to therapies

---

1️⃣ 10. Smith & Nephew plc

Headquarters: London, United Kingdom
Key Offering: ORTHOVISC, ORTHOVISC Mini

Smith & Nephew, a global medical technology company, offers the ORTHOVISC family of high molecular weight hyaluronic acid products. Their strength lies in combining viscosupplementation with their advanced arthroscopy and reconstruction portfolios.

Innovation and Market Initiatives:

• Integration with surgical and rehabilitation workflows
• Strong evidence generation for clinical outcomes
• Focus on the high-growth sports medicine segment

Get Full Report Here:
Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

---

🔬 Outlook: The Future of Viscosupplementation is Personalized and Advanced

The hyaluronic acid viscosupplementation market is evolving beyond simple joint lubrication. The industry is now focused on developing next-generation formulations that offer longer duration of effect, targeted drug delivery, and potentially disease-modifying capabilities.

📈 Key Trends Shaping the Market:

• R&D into combination products incorporating corticosteroids, anesthetics, or growth factors.
• Growing adoption of single-injection regimens due to better patient compliance and convenience.
• Increasing regulatory scrutiny and requirements for robust clinical evidence of efficacy.
• Expansion into new anatomical joints beyond the knee, such as the shoulder, hip, and ankle.

Get Full Report Here:
Hyaluronic Acid Viscosupplementation Market – View in Detailed Research Report

The companies profiled above are not merely supplying treatments; they are actively redefining the standard of care for millions of patients suffering from osteoarthritis worldwide, driving the shift toward more effective and less invasive therapeutic options.